Baseline characteristics of evaluable patients (n = 137)
| Characteristic . | Placebo (n = 67) . | Fenretinide (n = 70) . | ||
|---|---|---|---|---|
| Age (y) mean, median, range | 69.2, 70.9, 43.4-84.7 | 64.5, 64.0, 39.8-87.5 | ||
| Gender | ||||
| Male | 55 | 58 | ||
| Female | 12 | 12 | ||
| Race | ||||
| Black | 2 | 1 | ||
| Hispanic | 3 | 0 | ||
| Asian | 1 | 0 | ||
| White | 59 | 66 | ||
| Other | 2 | 3 | ||
| TCC characteristics | ||||
| Ta grade 1, grade 2 (no prior BCG) | ||||
| Solitary | 34 | 33 | ||
| Multifocal | 15 | 17 | ||
| Intermediate-risk, high-risk (prior BCG) | 18 | 20 | ||
| Smoking status | ||||
| Current | 16 | 16 | ||
| Former | 37 | 39 | ||
| Never | 14 | 15 | ||
| Characteristic . | Placebo (n = 67) . | Fenretinide (n = 70) . | ||
|---|---|---|---|---|
| Age (y) mean, median, range | 69.2, 70.9, 43.4-84.7 | 64.5, 64.0, 39.8-87.5 | ||
| Gender | ||||
| Male | 55 | 58 | ||
| Female | 12 | 12 | ||
| Race | ||||
| Black | 2 | 1 | ||
| Hispanic | 3 | 0 | ||
| Asian | 1 | 0 | ||
| White | 59 | 66 | ||
| Other | 2 | 3 | ||
| TCC characteristics | ||||
| Ta grade 1, grade 2 (no prior BCG) | ||||
| Solitary | 34 | 33 | ||
| Multifocal | 15 | 17 | ||
| Intermediate-risk, high-risk (prior BCG) | 18 | 20 | ||
| Smoking status | ||||
| Current | 16 | 16 | ||
| Former | 37 | 39 | ||
| Never | 14 | 15 | ||